|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:activeIngredient
|
gptkb:risperidone
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:associatedWith
|
gptkb:Abilify_Maintena
gptkb:Invega_Sustenna
|
|
gptkbp:ATCCode
|
N05AX08
|
|
gptkbp:brand
|
gptkb:risperidone
|
|
gptkbp:contraindication
|
hypersensitivity to risperidone
|
|
gptkbp:form
|
suspension for injection
long-acting injectable
|
|
gptkbp:frequency
|
every 2 weeks
|
|
gptkbp:genericAvailable
|
no (as of 2024)
|
|
gptkbp:halfLife
|
3 to 6 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Risperdal Consta
|
|
gptkbp:indication
|
bipolar disorder
schizophrenia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
gptkb:hyperprolactinemia
injection site reaction
weight gain
extrapyramidal symptoms
somnolence
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:bfsParent
|
gptkb:Invega_Sustenna
gptkb:risperidone
|
|
gptkbp:bfsLayer
|
7
|